A citation-based method for searching scientific literature

Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart, Nadine Tung, Paula D Ryan, Judy E Garber, Daniel P Silver, Zoltan Szallasi, Andrea L Richardson. Cancer Discov 2012
Times Cited: 298



Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, Kris Jardon, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley F Haggerty, Maria J Rubio-Pérez, Mark S Shahin, Giorgia Mangili, William H Bradley, Ilan Bruchim, Kaiming Sun, Izabela A Malinowska, Yong Li, Divya Gupta, Bradley J Monk. N Engl J Med 2019
Times Cited: 674




List of shared articles



Times cited

The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers.
Silvana Talisa Wijaya, Natalie Yl Ngoi, David Sp Tan. Best Pract Res Clin Obstet Gynaecol 2022
0

[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Hélène Salaün, Mathilde Saint-Ghislain, Audrey Bellesoeur, Philippe Beuzeboc, Cindy Neuzillet, Véronique Diéras, Marc Henri Stern, Manuel Rodrigues. Bull Cancer 2022
0

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
Lise M van Wijk, Andreea B Nilas, Harry Vrieling, Maaike P G Vreeswijk. Expert Rev Mol Diagn 2022
1

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
A Poveda, S Lheureux, N Colombo, D Cibula, K Lindemann, J Weberpals, M Bjurberg, A Oaknin, M Sikorska, A González-Martín,[...]. Gynecol Oncol 2022
2

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Jing Ni, Wenwen Guo, Qian Zhao, Xianzhong Cheng, Xia Xu, Rui Zhou, Hongyuan Gu, Chen Chen, Xiaoxiang Chen. Front Oncol 2022
1

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
Laetitia Collet, Julien Péron, Frédérique Penault-Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, Benoît You. Cancers (Basel) 2022
2



Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Jean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, Philipp Harter, Florence Joly, Ulrich Canzler, Caroline Truntzer, Olivier Tredan, Clemens Liebrich, Alain Lortholary,[...]. Cancers (Basel) 2022
0

Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Mark D Stewart, Diana Merino Vega, Rebecca C Arend, Jonathan F Baden, Olena Barbash, Nike Beaubier, Grace Collins, Tim French, Negar Ghahramani, Patsy Hinson,[...]. Oncologist 2022
4

Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Lola Paulet, Alexis Trecourt, Alexandra Leary, Julien Peron, Françoise Descotes, Mojgan Devouassoux-Shisheboran, Karen Leroy, Benoit You, Jonathan Lopez. Eur J Cancer 2022
0

Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.
Grace Moore, Rahul Majumdar, Simon N Powell, Atif J Khan, Nils Weinhold, Shen Yin, Daniel S Higginson. Mol Cancer Res 2022
1

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
E Rempel, K Kluck, S Beck, I Ourailidis, D Kazdal, O Neumann, A L Volckmar, M Kirchner, H Goldschmid, N Pfarr,[...]. NPJ Precis Oncol 2022
0


The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
Vilma Pacheco-Barcia, Andrés Muñoz, Elena Castro, Ana Isabel Ballesteros, Gloria Marquina, Iván González-Díaz, Ramon Colomer, Nuria Romero-Laorden. Cancers (Basel) 2022
0


The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Carolyn E Haunschild, Krishnansu S Tewari. Gynecol Oncol 2021
18

Homologous recombination repair deficiency (HRD): From biology to clinical exploitation.
David Gonzalez, Albrecht Stenzinger. Genes Chromosomes Cancer 2021
6

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Talia Golan, Grainne M O'Kane, Robert E Denroche, Maria Raitses-Gurevich, Robert C Grant, Spring Holter, Yifan Wang, Amy Zhang, Gun Ho Jang, Chani Stossel,[...]. Gastroenterology 2021
40

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-May Chen, Mihaela Cristea, Maria DeRosa, Eric L Eisenhauer,[...]. J Natl Compr Canc Netw 2021
119

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
2

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
11



Biomarkers for Homologous Recombination Deficiency in Cancer.
Svenja Wagener-Ryczek, Sabine Merkelbach-Bruse, Janna Siemanowski. J Pers Med 2021
12

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Zsofia Sztupinszki, Miklos Diossy, Judit Borcsok, Aurel Prosz, Nanna Cornelius, Maj K Kjeldsen, Mansoor R Mirza, Zoltan Szallasi. Clin Cancer Res 2021
7